131 related articles for article (PubMed ID: 3141331)
1. Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus.
Mitsunaga S; Kimura H; Yamaguchi Y; Mikata A
Jpn J Cancer Res; 1988 Aug; 79(8):965-72. PubMed ID: 3141331
[TBL] [Abstract][Full Text] [Related]
2. Enhanced biological activity of human recombinant interleukin 2 coupled to mouse red blood cells as evaluated using the mouse Meth A sarcoma model.
Moyes RB; Kirch H; DeLoach JR
Biotechnol Appl Biochem; 1996 Feb; 23(1):29-36. PubMed ID: 8867894
[TBL] [Abstract][Full Text] [Related]
3. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
[TBL] [Abstract][Full Text] [Related]
4. Role of anti-LFA-1 and anti-ICAM-1 combined MAb treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV).
Rosato A; Mandruzzato S; Bronte V; Zambon A; Macino B; Calderazzo F; Zanovello P; Collavo D
Int J Cancer; 1995 May; 61(3):355-62. PubMed ID: 7729948
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody against IFN-gamma inhibits Moloney murine sarcoma virus-specific cytotoxic T lymphocyte differentiation.
Zanovello P; Vallerani E; Biasi G; Landolfo S; Collavo D
J Immunol; 1988 Feb; 140(4):1341-4. PubMed ID: 2830339
[TBL] [Abstract][Full Text] [Related]
6. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area.
Rosato A; Zambon A; Macino B; Mandruzzato S; Bronte V; Milan G; Zanovello P; Collavo D
Int J Cancer; 1996 Mar; 65(6):847-51. PubMed ID: 8631602
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting passive monoclonal antibody therapy of Moloney sarcoma in BALB/c mice.
Kennel SJ; Lankford PK; Flynn KM; Winegar R
Cancer Res; 1985 Aug; 45(8):3782-9. PubMed ID: 2410101
[TBL] [Abstract][Full Text] [Related]
8. Murine sarcoma virus pseudotypes used as immunogens against viral and chemical oncogenesis.
BasombrÃo MA; Mayer AM; Pasqualini CD
Cancer Res; 1977 Jun; 37(6):1768-76. PubMed ID: 192461
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal IgM antibodies that inhibit primary Moloney murine sarcoma growth.
Lamon EW; Powell TJ; Walia AS; Lidin BI; Srinivas RV; Baskin JG; Kearney JF
J Natl Cancer Inst; 1987 Mar; 78(3):547-56. PubMed ID: 3469466
[TBL] [Abstract][Full Text] [Related]
10. Role of adhesion molecules in the immune reaction to M-MSV-induced tumors.
Rosato A; Bronte V; Mandruzzato S; Zambon A; Calderazzo F; Biasi G; Zanovello P; Collavo D
Int J Cancer Suppl; 1992; 7():24-7. PubMed ID: 1385341
[TBL] [Abstract][Full Text] [Related]
11. Temporary inhibition of Moloney-murine sarcoma virus (M-MSV) induced-tumours by adoptive transfer of ricin-treated T-lymphocytes.
Cerundolo V; Zanovello P; McIntosh D; Fabbris R; Davies AJ; Collavo D
Br J Cancer; 1987 Apr; 55(4):413-9. PubMed ID: 2437947
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody detects a common surface antigen on two independently established murine Moloney sarcoma virus non-producer transformants.
Weiland E; Thiel HJ
J Gen Virol; 1985 Sep; 66 ( Pt 9)():1863-72. PubMed ID: 2993478
[TBL] [Abstract][Full Text] [Related]
13. Induction of effective immunity to Moloney murine sarcoma virus using monoclonal anti-idiotypic antibody as immunogen.
Powell TJ; Spann R; Nguyenduc M; Lamon EW
J Immunol; 1989 Feb; 142(4):1318-24. PubMed ID: 2536772
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy of malignant tumors with subpopulations of T lymphocytes].
Fernández-Cruz E
Rev Esp Oncol; 1982; 29(4):701-10. PubMed ID: 6242320
[TBL] [Abstract][Full Text] [Related]
15. T-cell immunity to murine Moloney sarcoma virus-induced tumours: L3T4+ T cells are necessary for resistance to primary sarcoma growth, but Lyt-2+ T cells are required for resistance to secondary tumour cell challenge.
Bateman WJ; Jenkinson EJ; Owen JJ
Immunology; 1987 Jul; 61(3):317-20. PubMed ID: 2956180
[TBL] [Abstract][Full Text] [Related]
16. Tumors induced by progressor sarcoma virus (Moloney) in mice: growth in the presence of an immune response and isolation of autonomously growing cells.
Weiland E; Mussgay M
Arch Virol; 1980; 66(1):1-10. PubMed ID: 7436738
[TBL] [Abstract][Full Text] [Related]
17. Specific immunotherapy combined with whole body irradiation of BALB/c mice bearing Moloney murine sarcoma virus-induced primary tumors.
Kimura H; Yamaguchi Y; Fujisawa T
Gan; 1982 Jun; 73(3):446-53. PubMed ID: 6751920
[TBL] [Abstract][Full Text] [Related]
18. Tumor induction by murine sarcoma virus in AKR and C58 mice. Reduction of tumor regression associated with appearance of Gross leukemia virus pseudotypes.
Chieco-Bianchi L; Colombatti A; Collavo D; Sendo F; Aoki T; Fischinger PJ
J Exp Med; 1974 Nov; 140(5):1162-79. PubMed ID: 4608945
[TBL] [Abstract][Full Text] [Related]
19. Moloney murine sarcoma virus 349 induces Kaposi's sarcomalike lesions in Balb/c mice.
Stoica G; Hoffman J; Yuen PH
Am J Pathol; 1990 Apr; 136(4):933-47. PubMed ID: 2158239
[TBL] [Abstract][Full Text] [Related]
20. Induction of Moloney murine sarcoma virus tolerance in adult mice by anti-CD4 monoclonal antibody treatment.
Biasi G; Mazzocchi M; Facchinetti A; Panozzo M; Zanovello P; Collavo D; Chieco-Bianchi L
Cancer Res; 1990 Sep; 50(17 Suppl):5703S-5706S. PubMed ID: 2167167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
